R. Tasneen

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

This paper develops a DNA vaccine targeting dendritic cells that enhances isoniazid efficacy against tuberculosis by inducing strong immune responses and reducing Mtb burden.

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis

This study tests a new TB treatment regimen combining high-dose rifapentine and clofazimine in mouse models, finding it more effective than either drug alone in shortening treatment duration.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.